Stone JH, Wallace Z, Perugino CA, et al. Final Results of an Open Label Phase 2 Study of a Reversible B Cell Inhibitor, Xmab®5871, in IgG4-Related Disease. ACR 2017, abstract 4L.
Subsidie voor ontwikkeling tools voor snelle en accurate reumadiagnose
mei 2023 | Arteriitis, Arthritis psoriatica, Artritis, Artrose, JIA, Jicht, Sclerodermie, Sjögren, SLE, Spondyloartritis